Centessa Pharmaceuticals plc (NASDAQ:CNTA) Insider Karen M. Anderson Sells 10,624 Shares of Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) insider Karen M. Anderson sold 10,624 shares of the company’s stock in a transaction that occurred on Tuesday, December 17th. The stock was sold at an average price of $17.32, for a total transaction of $184,007.68. Following the transaction, the insider now owns 71,525 shares of the company’s stock, valued at approximately $1,238,813. This represents a 12.93 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Centessa Pharmaceuticals Price Performance

Centessa Pharmaceuticals stock opened at $17.55 on Friday. The stock’s 50 day moving average is $16.62 and its 200 day moving average is $13.51. Centessa Pharmaceuticals plc has a one year low of $6.65 and a one year high of $18.97. The firm has a market cap of $2.31 billion, a P/E ratio of -11.47 and a beta of 1.52. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.52 and a quick ratio of 21.52.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.37) EPS for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.05. As a group, research analysts expect that Centessa Pharmaceuticals plc will post -1.6 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have recently commented on CNTA shares. BMO Capital Markets increased their price target on Centessa Pharmaceuticals from $20.00 to $35.00 and gave the company an “outperform” rating in a research note on Monday, September 16th. Jefferies Financial Group increased their target price on Centessa Pharmaceuticals from $13.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, September 11th. B. Riley started coverage on Centessa Pharmaceuticals in a report on Thursday, September 19th. They set a “buy” rating and a $33.00 price target on the stock. Guggenheim raised their price objective on shares of Centessa Pharmaceuticals from $24.00 to $28.00 and gave the company a “buy” rating in a report on Friday, November 15th. Finally, Morgan Stanley upgraded shares of Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $11.00 to $26.00 in a research report on Thursday, September 19th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $25.83.

Institutional Trading of Centessa Pharmaceuticals

Institutional investors have recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Centessa Pharmaceuticals by 47.7% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company’s stock worth $40,000 after acquiring an additional 826 shares in the last quarter. GAMMA Investing LLC grew its stake in Centessa Pharmaceuticals by 103.1% during the third quarter. GAMMA Investing LLC now owns 2,972 shares of the company’s stock worth $48,000 after purchasing an additional 1,509 shares during the period. Quarry LP increased its holdings in Centessa Pharmaceuticals by 47.8% in the second quarter. Quarry LP now owns 9,608 shares of the company’s stock worth $87,000 after purchasing an additional 3,108 shares in the last quarter. Sandia Investment Management LP acquired a new position in Centessa Pharmaceuticals in the second quarter valued at approximately $90,000. Finally, Fred Alger Management LLC bought a new position in shares of Centessa Pharmaceuticals during the 2nd quarter worth approximately $99,000. Institutional investors own 82.01% of the company’s stock.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.